Author/Authors :
Yılmaz, Özlem Ondokuz Mayis University - Medical Faculty - Department of Dermatology, Turkey , Güler Özden, Müge Ondokuz Mayis University - Medical Faculty - Department of Dermatology, Turkey , Aydın, Fatma Ondokuz Mayis University - Medical Faculty - Department of Dermatology, Turkey , Şentürk, Nilgün Ondokuz Mayis University - Medical Faculty - Department of Dermatology, Turkey , Cantürk, Tayyar Ondokuz Mayis University - Medical Faculty - Department of Dermatology, Turkey , Turanlı, Ahmet Yaşar Ondokuz Mayis University - Medical Faculty - Department of Dermatology, Turkey
Abstract :
Cetuximab, is an IgG1 chimeric monoclonal antibody type of epidermal growth factor receptor (EGFR). It is most commonly prescribed for metastatic colorectal cancer, administered alone or in combination with irinotecan-based chemotherapy regimens (Lee et al., 2008; Segaert et al., 2005; Segaert and Cutsem 2005; Scope et al., 2009). Acneiform eruption is the most common adverse effect with 80% of incidence (Segaert and Cutsem 2005; Lee et al., 2008). We report two cases of severe acneiform eruption induced by cetuximab with metastatic colorectal cancer.
